One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels.

摘要: Entecavir and lamivudine are potent nucleoside analogues that can suppress hepatitis B virus (HBV) replication. However, the effects of these two antiviral agents on intrahepatic total HBV DNA covalently closed circular (cccDNA) not known. In this study, we aimed to assess effect 48 weeks entecavir/lamivudine therapy cccDNA levels. Forty chronic patients, participating in Phase III entecavir trials at our centre, were randomized receive either 0.5 mg once daily (n = 21) or 100 19). Their serological, virological biochemical responses, as well levels monitored. There was no significant difference between terms post-treatment responses. Both reduced serum viral load, DNA, by about 4.8 logs, 2 1 log respectively. An increase proportion form seen after therapy. conclusion, both successfully reduce cccDNA. CccDNA becomes dominant during suppression is possibly responsible for rebound short-term